Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement

Journal of Pharmacology and Experimental Therapeutics

Volumn 353, Issue 1, 2015, Pages 119-131

  Henne, Kirk R ^a   Ason, Brandon ^b   Howard, Monique ^c   Wang, Wei ^c   Sun, Jeonghoon ^c   Higbee, Jared ^c   Tang, Jie ^c   Matsuda, Katherine C ^a   Xu, Ren ^d   Zhou, Lei ^e   Chan, Joyce C Y ^b   King, Chadwick ^c   Piper, Derek E ^c   Ketchem, Randal R ^c   Michaels, Mark Leo ^c   Jackson, Simon M ^b   Retter, Marc W ^a  

^a AMGEN INC   (United States)

^b Metabolic Disorders   (United States)

^c Departments of Lead Discovery   (United States)

^d Genentech   (United States)

^e UCSF Dept Epidemiol Biostatist   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 MONOCLONAL ANTIBODY; SERINE PROTEINASE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENT; PCSK9 PROTEIN, HUMAN; PROTEIN BINDING;

ACID DISSOCIATION CONSTANT; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; ASSOCIATION RATE CONSTANT; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISSOCIATION CONSTANT; DISSOCIATION RATE CONSTANT; EC50; HALF LIFE TIME; MACACA FASCICULARIS; MALE; MOUSE; NEWBORN; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; ANIMAL; BLOOD; C57BL MOUSE; GENETICS; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; RHESUS MONKEY;

ANIMALS; ANTIBODIES, MONOCLONAL; CHOLESTEROL, LDL; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN FC FRAGMENTS; MACACA MULATTA; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROPROTEIN CONVERTASES; PROTEIN BINDING; RECEPTORS, FC; SERINE ENDOPEPTIDASES;

EID: 84928926586     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.221242     Document Type: Article

References (42)

1. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al. (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154-156.
2. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, et al.; Cholesterol Treatment Trialists' (CTT) Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-1681.
3. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, and Bekker PJ (2006) A study of the biological receptor activator of nuclear factorkappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221-1228.
4. Brown MS, Herz J, and Goldstein JL (1997) LDL-receptor structure: calcium cages, acid baths and recycling receptors. Nature 388:629-630.
5. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, and Konrad RJ (2008) Atorvastatin increases human serum levels of proprotein convertase subtilisin/ kexin type 9. J Lipid Res 49:394-398.
6. Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, Xia Z, et al. (2009) A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 106:9820-9825.
7. Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, et al. (2012) Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem 287:11090-11097.
8. Chen Y and Balthasar JP (2012) Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J 14:850-859.
9. Cohen JC, Boerwinkle E, Mosley TH, Jr, and Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264-1272.
10. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, and Langermann S (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171-5180.
11. Dall'Acqua WF, Kiener PA, and Wu H (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281: 23514-23524.
12. Davda JP and Hansen RJ (2010) Properties of a general PK/PD model of antibodyligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs 2:576-588.
13. Deng R, Jin F, Prabhu S, and Iyer S (2012) Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 8:141-160.
14. DeVay RM, Shelton DL, and Liang H (2013) Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). J Biol Chem 288: 10805-10818.
15. Finch DK, Sleeman MA, Moisan J, Ferraro F, Botterell S, Campbell J, Cochrane D, Cruwys S, England E, Lane S, et al. (2011) Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol 411:791-807.
16. Getz GS and Reardon CA (2012) Animal models of atherosclerosis. Arterioscler Thromb Vasc Biol 32:1104-1115.
17. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr, and Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239.
18. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vásquez M, et al. (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 279:6213-6216.
19. Hooper AJ and Burnett JR (2013) Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin Biol Ther 13:429-435.
20. Hopkins CR and Trowbridge IS (1983) Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. J Cell Biol 97: 508-521.
21. Horton JD, Cohen JC, and Hobbs HH (2007) Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32:71-77.
22. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, et al. (2010) Antibody recycling by engineered pHdependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 28:1203-1207.
23. Kuo TT and Aveson VG (2011) Neonatal Fc receptor and IgG-based therapeutics. MAbs 3:422-430.
24. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, and Horton JD (2006) Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 116: 2995-3005.
25. Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-252.
26. Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, Bai L, Abdiche Y, Dilley J, Yu J, et al. (2012) Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther 340:228-236.
27. National Research Council (2011) Guide for the Care and Use of Laboratory Animals, 8th ed, The National Academies Press, Washington, DC.
28. Ni YG, Di Marco S, Condra JH, Peterson LB, Wang W, Wang F, Pandit S, Hammond HA, Rosa R, Cummings RT, et al. (2011) A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res 52:78-86.
29. Ober RJ, Martinez C, Vaccaro C, Zhou J, and Ward ES (2004) Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol 172:2021-2029.
30. Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, and Walker NP (2007) The crystal structure of PCSK9: a regulator of plasma LDLcholesterol. Structure 15:545-552.
31. Pokala N and Handel TM (2005) Energy functions for protein design: adjustment with protein-protein complex affinities, models for the unfolded state, and negative design of solubility and specificity. J Mol Biol 347:203-227.
32. Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, and Griffin MP (2013) A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 57:6147-6153.
33. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, et al.; LAPLACE-2 Investigators (2014) Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE- 2 randomized clinical trial. JAMA 311:1870-1882.
34. Roopenian DC and Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725.
35. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, and Chretien M (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 100:928-933.
36. Stancu C and Sima A (2001) Statins: mechanism of action and effects. J Cell Mol Med 5:378-387.
37. Stein EA and Raal F (2014) Reduction of low-density lipoprotein cholesterol by monoclonal antibody inhibition of PCSK9. Annu Rev Med 65:417-431.
38. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, et al.; GAUSS-2 Investigators (2014) Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS- 2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 63:2541-2548.
39. Tabrizi M, Bornstein GG, and Suria H (2010) Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 12:33-43.
40. Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, and Fazio S (2013) Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation 127:2403-2413.
41. WangW, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, and Prueksaritanont T (2011) Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 39:1469-1477.
42. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, and Desjarlais JR (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28:157-159.